Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
· Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment · The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained · Consistently good safety and tolerability profile Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the ongoing phase 2a